

### **DETAILED ACTION**

This action is in response to the amendment filed July 13, 2009. Claims 99, 103 have been cancelled. Claims 41, 94, 100, 104 have been amended. All of the amendments have been thoroughly reviewed and entered. The previous rejections in the Office action mailed on 3/17/09 are withdrawn in view of the amendments.

### ***EXAMINER'S AMENDMENT***

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Applicant's representative Jeremy Jay on November 10, 2009.

Claims have been amended as follows.

Claim 41. (Currently Amended) A method of preparing dual specificity T lymphocytes comprising:

(i) ~~contacting T lymphocytes in a population of T lymphocytes ex vivo with a cell that is allogeneic to one or more T lymphocytes wherein the allogeneic cell is selected from the group consisting of dendritic cells, B lymphocytes and peripheral blood mononuclear cells (PBMCs), wherein contacting T lymphocytes with the allogeneic cell selects and specifically amplifies, from the population of T lymphocytes, T~~

lymphocytes comprising a T cell receptor that is reactive with the allogeneic cell; and

(i) contacting a population of T lymphocytes *ex vivo* with an allogeneic cell selected from the group consisting of dendritic cells, B lymphocytes and peripheral blood mononuclear cells (PBMCs), wherein contacting T lymphocytes with the allogeneic cell selects and specifically amplifies T lymphocytes comprising a T cell receptor that is reactive with the allogeneic cell; and

(ii) transducing the T lymphocytes comprising the T cell receptor reactive with the allogeneic cell with a chimeric receptor gene, said gene encoding a chimeric fusion receptor between a single chain antibody that recognizes a tumor antigen and a T cell receptor capable of triggering T cell receptor signal transduction, which is reactive with a tumor antigen, to produce dual specificity T lymphocytes, wherein the dual specificity T lymphocytes generate an anti-tumor immune response *in vivo*.

In claim 94, the phrase -- said transducing -- was inserted before "comprising" in line 1.

In claim 104, the phrase -- said contacting -- was inserted before "comprising" in line 1.

Claim 110. (Cancelled)

Claim 111. (Cancelled)

### ***Conclusion***

Claims 41, 94-98, 100-102, 104-109 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Q. JANICE LI** whose telephone number is 571-272-0730. The examiner can normally be reached on 9 AM -7:00pm, Monday through Friday, except every other Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph Weitach** can be reached on 571-272-0739. The **fax** numbers for the organization where this application or proceeding is assigned are **571-273-8300**.

Application/Control Number:  
09/803,578  
Art Unit: 1633

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

For all other customer support, please call the USPTO Call Center (UCC) at **800-786-9199**.

*/s/ JANICE LI/  
Primary Examiner, Art Unit 1633*